Oryzon Genomics - More data support vafidemstat for aggression
On 3 April 2020, Oryzon reported interim data for the first time from its two Phase IIa trials REIMAGINE-AD and ETHERAL. Both explore the company’s lead CNS asset vafidemstat (CNS-optimised LSD1 inhibitor) in Alzheimer’s disease (AD) patients, but in different disease subgroups and for different purposes. The REIMAGINE-AD study is focused on vafidemstat’s potential to control agitation and aggression seen in moderate to severe AD patients. The reported data was positive and echoed the findings from the other patient cohorts in the original REIMAGINE trial reported last year. Data from the ETHERAL trial are preliminary with interesting biomarker findings, but the clinical effect on patient cognition was not seen yet after six months of treatment (12-month treatment data should be available in Q221). Our valuation is marginally higher at €470m or €10.3 per share.Oryzon Genomics SA is a Spain-based biopharmaceutical company. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases. The Company's business model focuses on identifying biomarkers that can be translated in new therapeutic targets, as well as on investing in programs, mainly through the development of small molecules for two main indications: cancer and neurodegeneration. The Company develops investigational medicines till proof of concept (POC) phase and then partners the program with pharmaceutical entities, which are able to get the approval from drug agencies to bring these medicines to the patients. It cooperates with Roche. The Company is a subsidiary of Laboratorio Reig Jofre SA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.